The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

The Dow Jones Industrial Average is declining Friday morning with shares of Amgen and Amazon.com Inc. delivering the stiffest headwinds for the blue-chip average.

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

This study found that treatment with inebilizumab greatly reduced the symptoms of immunoglobulin G4–related disease (IgG4-RD), compared to placebo.

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Bernstein has recently initiated Amgen Inc (AMGN) stock to Outperform rating, as announced on October 17, 2024, according to Finviz. Earlier, on October 14, 2024, Truist had reduced the stock from a ...

Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.

On Monday, Amgen Inc (AMGN) stock saw a decline, ending the day at $316.91 which represents a decrease of $-2.31 or -0.72% from the prior close of $319.22. The stock opened at $320.58 and touched a ...